PRA Health Sciences (PRAH) Tops Q1 EPS by 4c, Revenues Beat; Offers 2Q EPS Below Consensus, 2Q Revs. Above Views, Withdraws FY20 Outlook

Go back to PRA Health Sciences (PRAH) Tops Q1 EPS by 4c, Revenues Beat; Offers 2Q EPS Below Consensus, 2Q Revs. Above Views, Withdraws FY20 Outlook

PRA Health Sciences (PRAH) PT Lowered to $103 at UBS

April 28, 2020 6:06 AM EDT

UBS lowered its price target on PRA Health Sciences (NASDAQ: PRAH) to $103.00 (from $116.00) while maintaining a Neutral rating.... More